Frohning Andrea L. 4

What Happened

• Andrea L. Frohning, Senior Vice President & CHRO of DENTSPLY SIRONA (XRAY), was granted a total of 148,386 equity instruments on March 4, 2026: 26,786 Restricted Stock Units (RSUs) and 121,600 stock options. Both awards show an acquisition price of $0.00 in the Form 4 (typical for compensation grants).
• The RSUs and options vest in annual one‑third increments over three years (see footnotes). The stock options have an exercise price equal to 110% of the issuer’s closing common‑stock price on the grant date, so they require the stock to rise above that level to have intrinsic value. This filing reports an award (compensation), not an open‑market purchase or sale.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (within the usual 2-business‑day window).
• Reported amounts: 26,786 RSUs (F1) and 121,600 derivative awards/options (F2); total covered = 148,386 instruments.
• Reported price: $0.00 for both awards (standard for grants).
• Vesting: RSUs vest one‑third annually over 3 years ending March 4, 2029 (F1). Options vest on the same schedule; exercise price = 110% of closing price on grant date (F2).
• Shares owned after transaction: not disclosed in the summary data provided.
• No 10b5‑1 plan, immediate sale, tax‑withholding sale, or late filing was indicated in the information supplied.

Context

• RSUs: subject to time‑based vesting; value realized only as they vest and convert to shares.
• Options: require the stock to exceed the 110% exercise price to be valuable; they are incentive compensation tied to future stock performance.
• Grants are common executive compensation and do not, by themselves, indicate buying or selling intent in the open market.